Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 260

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 10
Chunk 260
---
 March 27, 2025, that the clin ical study will be terminated early as Sanofi will now pursue the development of IPH6401/SAR'514 in autoimmune indications.

Research Collaboration and Licensing agreement (2022) relating to Innate’s ANKET® program - IPH62 and IPH67

IPH62

In December 2022, the Company entered into a research collaboration and licensing agreement with Genzyme Corporation, a wholly owned subsidiary of Sanofi under which the Company grants Sanofi an exclusive license to Innate’s B7H3 ANKET® program (IPH62) and options for two additional targets to be named. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.

Under the terms of the research collaboration and license agreement, Innate has received in March 2023 €25 million as upfront payment and will receive, during the term of the Research and Collaboration Agreement, up to €1.35 billion total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.

IPH67

On December 19, 2023, Innate announced that Sanofi had exercised its option to license a natural killer (NK) cell engager program in solid tumors from the Company’s ANKET® platform (IPH67) pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization. Sanofi still retains the option to one additional ANKET® target as per the research collaboration and licensing agreement with Genzyme Corporation. Under the terms of the research collaboration and licensing agreement, the Company has received a €15 million payment for the exercise of this option. The Company is eligible for up to €1.35 billion total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.

During the third quarter 2024, Sanofi terminated the IPH67 license. As a consequence, Innate has regained the full rights to IPH67, an NK-cell engager program in solid tumors from Innate’s ANKET® platform. As a result of such termination and resumptions of rights, Sanofi retains a right to compensation regarding any future revenue that Innate Pharma may receive for licenses of or assigning rights related to Nectin-4, as well as payments based on milestones upon certain authorizations being obtained should the Company develop IPH67 itself, and an